4-chloro-N-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide | 1421609-39-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-chloro-N-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide
• 英文别名: N-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-chlorobenzamide；4-chloro-N-(1,4-dioxonaphthalen-2-yl)benzamide
• CAS: 1421609-39-3
• 化学式: C₁₇H₁₀ClNO₃
• 分子量: 311.724
• InChiKey: UTLDBATYFHNJKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,4-萘醌 在 sodium azide 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 、 mineral oil 为溶剂， 反应 6.08h， 生成 4-chloro-N-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)benzamide
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY
  [FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES OU DE LÉSIONS NEUROLOGIQUES

  摘要：

  提供了用于治疗神经系统疾病或损伤的化合物，包括神经退行性疾病、中风、创伤、癫痫、急性和慢性肾脏损伤、糖尿病和/或癫痫。在某些实施例中，提供了维生素K的衍生物。

  公开号：

  WO2014074976A1

文献信息

• Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor
  作者：Cheng Zhang、C. James Chou

  DOI：10.1021/acs.orglett.6b02740

  日期：2016.11.4

  A novel synthetic approach to amidoquinones by the reaction of naphthoquinones with hydroxamic acids under basic conditions was developed. The reaction is mild and operationally simple, and it affords high yields of amidoquinones. With this new method, a novel, very strong HDAC6 inhibitor, which showed high toxicity to AML cells, was successfully synthesized.

  开发了一种在碱性条件下萘醌与异羟肟酸反应合成酰胺基醌的新方法。该反应温和且操作简单，并提供了高产率的酰胺基醌。通过这种新方法，成功合成了一种新型的非常强的HDAC6抑制剂，该抑制剂对AML细胞显示出高毒性。
• [EN] METHOD FOR INHIBITING TRYPANSOMA CRUZI<br/>[FR] PROCÉDÉ D'INHIBITION DE TRYPANSOMA CRUZI
  申请人：UNIV HOWARD

  公开号：WO2013016661A1

  公开（公告）日：2013-01-31

  In its broadest aspect, a method for treating a mammalian patient at risk or suffering from a disease caused by a kinetoplastid parasite comprises administering to such subject an effective kinetoplasticidal amount of an imido-substituted 1,4- naphthoquinone to inhibit the kinetoplastid. In an important aspect, a method of inhibiting Trypanosoma cruzi comprises administering to a patient for prophylaxis or to a patient in need of treatment an antitrypanosomal effective amount of an imido-substituted 1 A-naphthoquinone.

  在其最广泛的方面，一种治疗受威胁或患有由原生质体寄生虫引起的疾病的哺乳动物患者的方法包括向该受试者施用有效的威力质体杀灭剂量的亚胺取代的1,4-萘醌以抑制威力体。在一个重要方面，一种抑制克氏锥虫的方法包括向需要预防或治疗的患者施用亚胺取代的1 A-萘醌的抗克氏锥虫有效量。
• COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES OR INJURY
  申请人：MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

  公开号：US20150320702A1

  公开（公告）日：2015-11-12

  Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

  提供了用于治疗神经系统疾病或损伤的化合物，包括神经退行性疾病、中风、创伤、癫痫、急性和慢性肾脏损伤、糖尿病和/或癫痫。在某些实施例中，提供了维生素K的衍生物。
• Compositions and methods for treating neurological diseases or injury
  申请人：MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

  公开号：US10391070B2

  公开（公告）日：2019-08-27

  Provided are compounds for the treatment of neurological diseases or injuries, including neurodegenerative diseases, stroke, trauma, epilepsy, acute and chronic kidney injuries, diabetes mellitus, and/or seizures. In some embodiments, derivatives of vitamin K are provided.

  所提供的化合物用于治疗神经系统疾病或损伤，包括神经退行性疾病、中风、创伤、癫痫、急性和慢性肾损伤、糖尿病和/或癫痫发作。 在某些实施方案中，提供了维生素 K 的衍生物。
• Structure–Activity Relationship Study of Vitamin K Derivatives Yields Highly Potent Neuroprotective Agents
  作者：Benjamin J. Josey、Elizabeth S. Inks、Xuejun Wen、C. James Chou

  DOI：10.1021/jm301485d

  日期：2013.2.14

  Historically known for its role in blood coagulation and bone formation, vitamin K (VK) has begun to emerge as an important nutrient for brain function. While VK involvement in the brain has not been fully explored, it is well-known that oxidative stress plays a critical role in neuro-degenerative diseases. It was recently reported that VK protects neurons and oligodendrocytes from oxidative injury and rescues Drosophila from mitochondrial defects associated with Parkinson's disease. In this study, we take a chemical approach to define the optimal and minimum pharmacophore responsible for the neuroprotective effects of VK. In doing so, we have developed a series of potent VK analogues with favorable drug characteristics that provide full protection at nanomolar concentrations in a well-defined model of neuronal oxidative stress. Additionally, we have characterized key cellular responses and biomarkers consistent with the compounds' ability to rescue cells from oxidative stress induced cell death.